Definium's LSD-Based Anxiety and Depression Drug Achieves Further Success in a Clinical Trial

Definium announced that its drug candidate for LSD-based treatment of anxiety and depression achieved further positive results in a clinical trial. The company stated that the primary objectives of the study were met. The trial was designed to evaluate the efficacy and safety of the drug. The data obtained show that the treatment provided a statistically significant improvement. Definium's success reflects the growing interest in psychedelic-based treatments in the field of mental health. The company announced that it will continue discussions with regulatory authorities for the next phase. Not investment advice.

📊 GOOGL — Piyasa Yorumu

■ neutral · 30%

The news headline is not directly related to GOOGL; it concerns a clinical trial by a company called Definium. Therefore, no significant short-term impact on GOOGL stock is expected. Technical indicators point to an overbought zone: RSI14 at 73.5 and the price has increased by 5.76% in 24 hours. MACD is positive and above the signal line, short-term momentum is strong but carries the risk of an overbought correction. While the news impact is considered neutral, the technical outlook is mixed; it is advisable to be cautious.

RSI 14

73.5

MACD

3.52

24h Δ

5.76%

Canlı Grafikler